Yahoo Finance • last year
In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story
Yahoo Finance • last year
- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of lead subcutaneous (SC) program in TED planned for year-end 2023 - - Company adds mu... Full story
Yahoo Finance • 2 years ago
WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious an... Full story
Yahoo Finance • 2 years ago
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announc... Full story
Yahoo Finance • 2 years ago
- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program - - Platform presentation to feature data from ongoing Phase 1/2 trial of VRDN-001 - - Poster presentations to... Full story
Yahoo Finance • 2 years ago
WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today annou... Full story
Yahoo Finance • 2 years ago
- Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED) - - First patient enrolled in ‘THRIVE’ Phase 3 trial in patients with active TED, with results expected in mid-2... Full story
Yahoo Finance • 2 years ago
- Data from ongoing Phase 1/2 trial of VRDN-001 to be presented during oral platform session - - Additional poster presentations to cover trial design, early-stage clinical and mechanistic data on pipeline candidates in Company’s thyroid... Full story
Yahoo Finance • 2 years ago
WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today annou... Full story
Yahoo Finance • 2 years ago
WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announ... Full story
Yahoo Finance • 2 years ago
WALTHAM, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announ... Full story
Yahoo Finance • 2 years ago
WALTHAM, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announ... Full story
Yahoo Finance • 2 years ago
WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious a... Full story
Yahoo Finance • 2 years ago
兩次輸注 3 mg/kg 後,TED 的體徵和症狀均有顯著且迅速的改善,與之前 10 和 20 mg/kg 的結果基本一致在 3 mg/kg VRDN-001 治療的患者中,67% 獲得眼球突出反應,56% 獲得總體反應,67% 達到臨床活動評分 (CAS) 為 0 或 1,20% 的複視完全消退迄今為止,在接受 VRDN-001 治療的所有 21 名患者中,71% 獲得眼球突出反應,67% 獲得總體反應,62% 達到CAS 為 0 或 1,54% 的複視完全消退,所有劑量... Full story
Yahoo Finance • 2 years ago
3 mg/kgを2回静注投与した後、TEDの徴候および症状の両方が有意かつ迅速に改善し、10 mg/kgおよび20 mg/kgの先行成績と概ね一致3 mg/kgのVRDN-001を投与された患者のうち、67%が眼球突出に奏功、56%に全体的な奏功、67%が臨床活動スコア (CAS) 0または1を達成し、20%で複視が完全に消失これまでにVRDN-001を投与された21名の患者のうち、71%が眼球突出に奏功、67%に全体的な奏功、62%が臨床活動スコア (CAS) 0または1... Full story
Yahoo Finance • 2 years ago
- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results – - Among 3 mg/kg VRDN-001 treated patients, 67% were proptosis responders, 56%... Full story
Yahoo Finance • 2 years ago
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announ... Full story
Yahoo Finance • 2 years ago
- The global THRIVE Phase 3 trial will be conducted in approximately 50 centers across North America and Europe - - Topline results for the THRIVE Phase 3 trial are expected in the middle of 2024 – WALTHAM, Mass., Dec. 21, 2022 (GLOBE... Full story
Yahoo Finance • 2 years ago
WALTHAM, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced... Full story
Yahoo Finance • 2 years ago
- Significant and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 20 mg/kg VRDN-001; generally consistent with 10mg/kg results at week 6 - - Global Phase 3 THRIVE clinical program initiated - - Ended... Full story